Cacco, Inc. (4166) AI Stock Analysis

• Market Cap: ¥2.21B
• Dividend Yield: N/A
• Average Volume (3M): 40.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: 12.27%
• EPS Growth: 73.45%
• Country: JP
• Employees: 35
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): -6.75
• Shares Outstanding: 2,732,655
• 10 Day Avg. Volume: 11,830
• 30 Day Avg. Volume: 40,016
• PEG Ratio: 0.29
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 2.24
• P/FCF Ratio: -8.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: ¥817.00 ▼(-8.00% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, with significant declines in revenue and profitability, and negative cash flows. Despite these challenges, the stock shows positive technical momentum, which provides some support. However, the negative P/E ratio and lack of dividend yield highlight valuation concerns.

Positive Factors

Low leverage / strong equity

A very high equity ratio and minimal leverage provide durable financial flexibility, lowering bankruptcy risk and preserving borrowing capacity. This balance sheet strength supports sustained R&D and product investments, and gives time to execute turnaround without urgent refinancing.

Recurring subscription revenue

Subscription-based telemedicine revenue creates predictable, recurring cash inflows and higher customer lifetime value over time. This business model supports stable revenue visibility, cross-sell opportunities with EHR/analytics, and long-term client relationships that improve retention and monetization.

Diversified healthcare software suite

A product portfolio spanning EHR, telemedicine and analytics reduces reliance on a single product, enabling cross-selling into hospitals and clinics. This breadth aligns with structural digital health trends and enhances customer stickiness, supporting sustainable revenue streams if execution remains consistent.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flows undermine the company's ability to self-fund operations, R&D and customer support. Over months, this increases dependence on external financing or dilution, constrains strategic flexibility, and raises execution risk for long-term growth initiatives.

Eroding margins and losses

Declining gross margins and negative net margins signal structural pricing pressure or rising costs that impair profitability. Sustained margin erosion reduces capacity to invest in product development and sales, making it harder to reach scalable, self-sustaining operations over the medium term.

Revenue decline and operational setbacks

A pronounced revenue decline erodes scale, weakens market positioning and may indicate lost customers or competitive disadvantage. Combined with limited headcount, declining top-line hurts long-term economics and necessitates structural fixes to product-market fit, sales execution, or pricing strategy.

Cacco, Inc. Business Overview & Revenue Model

Company Description

Cacco, Inc. (4166) is a technology-driven company specializing in software solutions for the healthcare sector. The company develops innovative applications aimed at improving patient care and operational efficiency within hospitals and clinics. Cacco, Inc. offers a range of products, including electronic health record (EHR) systems, telemedicine platforms, and healthcare analytics tools that empower healthcare providers to enhance service delivery and patient outcomes.

How the Company Makes Money

Cacco, Inc. generates revenue primarily through the sale of its software products and subscription-based services. The company charges healthcare providers a licensing fee for its EHR systems, which typically includes installation, maintenance, and support services. Additionally, Cacco, Inc. earns recurring revenue from subscription fees associated with its telemedicine platform, where healthcare facilities pay monthly or annual fees based on usage. Key revenue streams also include revenue from consulting services and customized solutions for larger healthcare organizations. Strategic partnerships with major healthcare systems and technology firms further bolster its earnings by expanding its customer base and enhancing its product offerings.

Cacco, Inc. Financial Statement Overview

Summary

Cacco, Inc. is experiencing financial difficulties with declining revenues and profitability, as well as negative cash flows. Despite a strong equity position, the company faces operational challenges that impact its financial health.

Income Statement

Cacco, Inc. has experienced a significant decline in revenue and profitability. The gross profit margin has decreased from 67.8% in 2022 to 60.6% in 2024, and the net profit margin is negative, indicating losses. Revenue growth has been negative, with a 22.9% decline from 2023 to 2024. The company is also facing negative EBIT and EBITDA margins, reflecting operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 81.2% in 2024, indicating financial stability. The debt-to-equity ratio is low at 0.1, suggesting low leverage. However, the return on equity has turned negative due to net losses, which is a concern for profitability.

Cash Flow

Cacco, Inc. is facing cash flow challenges with negative operating and free cash flows in 2024. The free cash flow to net income ratio is unfavorable, and the operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	793.43M	734.02M	952.00M	1.08B	951.14M	831.35M
Gross Profit	514.85M	445.02M	586.50M	729.95M	690.91M	587.78M
EBITDA	-132.73M	-211.00M	-215.67M	244.87M	191.91M	131.56M
Net Income	-170.32M	-255.03M	-320.00M	100.35M	120.31M	130.03M
Balance Sheet
Total Assets	996.00M	1.03B	1.29B	1.53B	1.42B	1.82B
Cash, Cash Equivalents and Short-Term Investments	684.00M	734.00M	941.00M	962.07M	800.65M	1.29B
Total Debt	98.00M	82.14M	96.00M	1.80M	6.08M	510.19M
Total Liabilities	210.00M	193.10M	214.00M	161.13M	143.98M	674.49M
Stockholders Equity	786.00M	832.17M	1.07B	1.37B	1.27B	1.15B
Cash Flow
Free Cash Flow	0.00	-200.00M	-56.00M	212.50M	21.94M	-3.94M
Operating Cash Flow	0.00	-198.00M	-49.31M	250.38M	149.66M	166.75M
Investing Cash Flow	0.00	-2.06M	-69.68M	-86.61M	-134.25M	-197.67M
Financing Cash Flow	0.00	-5.68M	98.01M	-2.34M	-507.94M	734.08M

Cacco, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 888.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4166, the sentiment is Neutral. The current price of 888 is above the 20-day moving average (MA) of 828.05, above the 50-day MA of 765.32, and above the 200-day MA of 741.83, indicating a neutral trend. The MACD of 5.95 indicates Positive momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 21.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4166.

Cacco, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5028	70 Outperform	¥3.29B	20.17	―	―	33.55%	293.32%
5256	69 Neutral	¥3.26B	15.39	―	―	13.48%	61.77%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
4052	55 Neutral	¥1.76B	-29.29	―	―	-9.71%	-1076.54%
4166	53 Neutral	¥2.21B	-16.36	―	―	12.27%	73.45%
4199	52 Neutral	¥3.97B	-21.44	―	―	-5.44%	-242.43%

Cacco, Inc. Corporate Events

Cacco Inc. Reports Q3 2025 Financial Results with Increased Sales Amid Losses

Cacco Inc. reported its financial results for the third quarter of fiscal year 2025, showing a notable increase in net sales by 14.9% compared to the previous year, despite continuing to operate at a loss. The company’s financial position remains stable with a high capital ratio, and no changes have been made to its dividend or financial forecasts, indicating a cautious approach towards future growth.

The most recent analyst rating on (JP:4166) stock is a Sell with a Yen637.00 price target. To see the full list of analyst forecasts on Cacco, Inc. stock, see the JP:4166 Stock Forecast page.